Skip to main content

Table 5 Multivariable analyses of anthracycline-treated patients, N = 99*

From: Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study

   DFS   OS  
   HR (95% CI) P HR (95% CI) P
TIMP-1 Continuous variable 1.75 (1.00-3.07) 0.05 4.19 (1.67-10.51) 0.002
  High vs. low 1.48 (0.84-2.61) 0.17 2.59 (1.14-5.88) 0.02
Age 41-55 years vs. ≤ 40 years 0.68 (0.37-1.25) 0.22 0.80 (0.37-1.72) 0.57
Tumor size Stage 2 (> 2 cm) vs. stage 1 (≤ 2 cm) 2.13 (0.91-4.98) 0.13 3.63 (0.82-16.13) 0.14
  Stage 3 (>5 cm or chest wall/skin involvement) vs. stage 1 (≤ 2 cm) 2.31 (0.87-6.11)   2.77 (0.54-14.14)  
Grade Unknown vs. poor 0.90 (0.43-1.92) 0.88 0.16 (0.02-1.21) 0.06
  Well/moderate vs. poor 0.82 (0.35-1.88)   1.11 (0.39-3.15)  
  1. * Analyses stratified for hormone receptor status, nodal status and RT on the axilla. The results for age, tumor size and grade are from the base model not including TIMP-1. TIMP-1 was added separately as a continuous variable and then as a dichotomized one. The coefficients for age, tumor size and grade were similar with TIMP-1 included.